Saad Z. Usmani, MD, MBA, FACP

Dr. Usmani is Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York.

Articles by Saad Z. Usmani, MD, MBA, FACP

Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 31, 2024
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | March 15, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPVideo Insights | January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
Thomas Martin, MDMyeloma | February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Amrita Krishnan, MD, FACPPrint | May 30, 2023
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | November 14, 2022
Experts discuss treatment options related to anti-CD38 based combination triplets.
Saad Z. Usmani, MD, MBA, FACPMyeloma | November 14, 2022
Experts focus on the latest news and clinical development and impact for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | November 14, 2022
Drs. Saad Usumani and Sydney Lu discuss adjusting multiple myeloma treatments to the realities of the COVID-19 pandemic.
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 13, 2021
Communication, clarity, patient education, and support from the healthcare team can all contribute to adherence to therapy.
Saad Z. Usmani, MD, MBA, FACPMyeloma | November 14, 2022
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Saad Z. Usmani, MD, MBA, FACPMyeloma | November 14, 2022
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...